Expansion opportunities Astellas is actively expanding its global footprint, including recent office expansion into China and Dublin, Ireland. This presents sales opportunities for local partnerships, regional supply chain enhancements, and region-specific compliance or IT services that support rapid scaling and cross-border operations.

Tech and compliance The company employs a robust tech stack with cloud infrastructure (AWS), data storage (S3), ERP/financial systems (SAP Financial Accounting), and security/vulnerability tools (Tenable). This indicates potential for cybersecurity, cloud optimization, data analytics, and integrated enterprise solutions tailored to regulated life sciences environments.

R&D and partnerships With a focus on oncology, ophthalmology, urology, immunology, and women's health, Astellas prioritizes innovative science and high unmet medical needs. This suggests opportunities in collaboration, licensing, and data-driven R&D support, including digital health platforms, real-world evidence, and clinical data management services.

Strategic leadership Recent leadership change in chief strategy officer indicates ongoing strategic realignment and potential new initiatives. This can translate to targeted partnership prospects, strategic outsourcing, and advisory services aligned with their evolving growth agenda.

Competitive and market signals Industry signals show competition from Eli Lilly and other peers in key disease areas. Proactively offering competitive intelligence, market access analytics, early-stage collaboration opportunities, and value communications support could help Astellas differentiate and accelerate its pipeline advancement.